查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
Alpha地中海型貧血治療的全球市場-成長，未來展望，競爭分析(2022年～2030年)
市場調查報告書
商品編碼
1149078

Alpha地中海型貧血治療的全球市場-成長，未來展望，競爭分析(2022年～2030年)

Alpha Thalassemia Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 120 Pages | 商品交期: 最快1-2個工作天內

價格

全球Alpha地中海型貧血治療的市場規模在2021年達到6億4,340萬美元，在2021年到2029年間的年複合成長率預測將為7.1％。醫護人員和一般市民對地中海型貧血相關的意識提升，為了管理·治療地中海型貧血政府·非官方機構所提供的支援，促進了Alpha地中海型貧血治療市場的成長。

本報告提供全球Alpha地中海型貧血治療市場相關調查分析，提供商務展望，市場動態，市場分析，企業簡介等系統性資訊。

目錄

第1章 序文

  • 報告的說明
    • 報告的目的
    • 對像者
    • 主要的產品
  • 市場區隔
  • 調查手法
    • 階段Ⅰ-2次調查
    • 階段Ⅱ-1次調查
    • 階段Ⅲ-專家的審查
    • 假設
    • 所採用的方法

第2章 摘要整理

  • 市場概述:全球Alpha地中海型貧血治療市場
  • 全球Alpha地中海型貧血治療市場(100萬美元)(2021年)
  • 全球Alpha地中海型貧血治療市場(100萬美元)(2021年):各藥物類型
  • 全球Alpha地中海型貧血治療市場(100萬美元)(2021年):各地區
  • COVID-19影響
  • 富有魅力的投資提案(2021年):各地區
  • 競爭分析
    • 主要的Alpha地中海型貧血治療市場供應商的市場定位
    • Alpha地中海型貧血治療市場供應商採用的策略
    • 主要的產業策略

第3章 Alpha地中海型貧血治療市場:商務展望和市場動態

  • 簡介
  • 全球Alpha地中海型貧血治療市場金額(100萬美元)(2020年～2030年)
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要課題
    • 主要的機會
  • 促進因素與阻礙因素的影響分析
  • Seesaw分析
  • 波特的五力分析
    • 供應商的力量
    • 買主的力量
    • 替代品的威脅
    • 新加入廠商業者的威脅
    • 競爭企業間的敵對關係
  • PESTEL分析
    • 政治
    • 經濟
    • 技術性
    • 法律
    • 社會

第4章 Alpha地中海型貧血治療市場:美金(100萬)(2020年～2030年)

  • 市場概要
  • 成長和收益分析:2021年和2030年的比較
  • 市場區隔

第5章 Alpha地中海型貧血治療市場，美金(100萬)(2020年～2030年):各藥物類型

  • 市場概要
  • 成長和收益分析:2021年和2030年的比較
  • 市場區隔
    • 葉酸
    • 地拉羅司
    • 去鐵酮
    • 羥基尿

第6章 北美的Alpha地中海型貧血治療市場，美金(100萬)(2020年～2030年)

第7章 英國及歐洲聯盟的Alpha地中海型貧血治療市場，美金(100萬)(2020年～2030年)

第8章 亞太地區的Alpha地中海型貧血治療市場，美金(100萬)(2020年～2030年)

第9章 南美的Alpha地中海型貧血治療市場，美金(100萬)(2020年～2030年)

第10章 中東及非洲的Alpha地中海型貧血治療市場，美金(100萬)(2020年～2030年)

第11章 企業簡介

  • GlaxoSmithKline Plc
  • Bellicum Pharmaceuticals
  • Novartis AG
  • Acceleron Pharma
  • Johnson & Johnson
  • Merck & Co Inc.
  • Alnylam Pharmaceuticals Inc.
  • Calimmune Inc.
  • Editas Medicine Inc.
  • Gilead Sciences Inc.
Product Code: 138733-08-22

Industry Outlook

Alpha thalassemia treatment market accounted for a market value of US$ 643.4 Mn in 2021 and projected to grow at a CAGR of 7.1% during the forecast period from 2022 to 2030. Alpha thalassemia is a congenital autosomal recessive disorder caused due to absence or reduction in alpha globin peptides due to a deletion or mutation of the alpha globin genes. Alpha thalassemia usually found in Africa, the Middle East, India, Southeast Asia, southern China, and the Mediterranean region. The key factors responsible for growth of alpha thalassemia treatment market are the rising awareness associated with thalassemia in medical practitioners & public, and support provided by government & non-government organizations to manage and treat thalassemia.

Deferasirox being the only approved drug for alpha thalassemia treatment will dominate the market throughout the forecast period

In 2021, deferasirox will dominate the market throughout the forecast period as it is the only approved drug therapy by USFDA for alpha thalassemia. According to market experts, deferasirox possess efficient oral bioavailability and a long half-life appropriate for once-daily dosing. Overall, deferasirox is similar to deferoxamine in reducing liver iron and serum ferritin levels in a dose-dependent style. It is use widely across the world for alpha thalassemia treatment because its once-per-day oral dosage. However, Darbepoetin Alfa is present in phase III of clinical trials and expected to get approval very soon but there are a few drawbacks observed in the Phase IIa that might have some effect on its approval. If it gets approved it will be observed as the fastest growing drug in this market.

Increasing awareness related to the treatment & management of alpha thalassemia in Asia Pacific makes it the fastest growing region throughout the forecast period

The Asia Pacific will grow gradually throughout the forecast period from 2020 to 2030, the key factors responsible for growth of alpha thalassemia treatment market in this region are rising awareness related to alpha thalassemia treatment & management and increasing support provided by governmental & non-governmental organizations to develop awareness in public. According to market experts, alpha-thalassemia is specifically common among Southeast Asian population descent 1-30% of the population has a thalassemia trait; up to 40% may be a genetic carrier.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Alpha Thalassemia Treatment market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Alpha Thalassemia Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Type

  • Folic Acid
  • Deferasirox
  • Deferiprone
  • Hydroxyurea

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Alpha Thalassemia Treatment market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Alpha Thalassemia Treatment market?
  • Which is the largest regional market for Alpha Thalassemia Treatment market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Alpha Thalassemia Treatment market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Alpha Thalassemia Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Alpha Thalassemia Treatment Market
  • 2.2. Global Alpha Thalassemia Treatment Market, By , 2021 (US$ Million)
  • 2.3. Global Alpha Thalassemia Treatment Market, By Drug Type, 2021 (US$ Million)
  • 2.4. Global Alpha Thalassemia Treatment Market, By Geography, 2021 (US$ Million)
  • 2.5. Impact of Covid 19
  • 2.6. Attractive Investment Proposition by Geography, 2021
  • 2.7. Competitive Analysis
    • 2.7.1. Market Positioning of Key Alpha Thalassemia Treatment Market Vendors
    • 2.7.2. Strategies Adopted by Alpha Thalassemia Treatment Market Vendors
    • 2.7.3. Key Industry Strategies

3. Alpha Thalassemia Treatment Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Alpha Thalassemia Treatment Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation

5. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Folic Acid
    • 5.3.2. Deferasirox
    • 5.3.3. Deferiprone
    • 5.3.4. Hydroxyurea

6. North America Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
  • 6.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
  • 6.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.4.1.North America
      • 6.4.1.1. U.S.
      • 6.4.1.2. Canada
      • 6.4.1.3. Rest of North America

7. UK and European Union Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
  • 7.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
  • 7.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.4.1.UK and European Union
      • 7.4.1.1. UK
      • 7.4.1.2. Germany
      • 7.4.1.3. Spain
      • 7.4.1.4. Italy
      • 7.4.1.5. France
      • 7.4.1.6. Rest of Europe

8. Asia Pacific Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
  • 8.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
  • 8.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.4.1.Asia Pacific
      • 8.4.1.1. China
      • 8.4.1.2. Japan
      • 8.4.1.3. India
      • 8.4.1.4. Australia
      • 8.4.1.5. South Korea
      • 8.4.1.6. Rest of Asia Pacific

9. Latin America Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
  • 9.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
  • 9.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.4.1.Latin America
      • 9.4.1.1. Brazil
      • 9.4.1.2. Mexico
      • 9.4.1.3. Rest of Latin America

10. Middle East and Africa Alpha Thalassemia Treatment Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Alpha Thalassemia Treatment Market: By , 2020-2030, USD (Million)
  • 10.3. Alpha Thalassemia Treatment Market: By Drug Type, 2020-2030, USD (Million)
  • 10.4.Alpha Thalassemia Treatment Market: By Region, 2020-2030, USD (Million)
    • 10.4.1.Middle East and Africa
      • 10.4.1.1. GCC
      • 10.4.1.2. Africa
      • 10.4.1.3. Rest of Middle East and Africa

11. Company Profile

  • 11.1. GlaxoSmithKline Plc
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Bellicum Pharmaceuticals
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Novartis AG
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Acceleron Pharma
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Johnson & Johnson
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. Merck & Co Inc.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Alnylam Pharmaceuticals Inc.
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Calimmune Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Editas Medicine Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Gilead Sciences Inc.
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
  • TABLE 2 Global Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 3 North America Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
  • TABLE 4 North America Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 5 UK and European Union Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
  • TABLE 6 UK and European Union Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 7 Asia Pacific Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
  • TABLE 8 Asia Pacific Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 9 Latin America Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
  • TABLE 10 Latin America Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)
  • TABLE 11 Middle East and Africa Alpha Thalassemia Treatment Market By , 2020-2030, USD (Million)
  • TABLE 12 Middle East and Africa Alpha Thalassemia Treatment Market By Drug Type, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Alpha Thalassemia Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Alpha Thalassemia Treatment Market: Quality Assurance
  • FIG. 5 Global Alpha Thalassemia Treatment Market, By , 2021
  • FIG. 6 Global Alpha Thalassemia Treatment Market, By Drug Type, 2021
  • FIG. 7 Global Alpha Thalassemia Treatment Market, By Geography, 2021
  • FIG. 8 Global Alpha Thalassemia Treatment Market, By , 2021 Vs 2030, %
  • FIG. 9 Global Alpha Thalassemia Treatment Market, By Drug Type, 2021 Vs 2030, %
  • FIG. 10 U.S. Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 11 Canada Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Rest of North America Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 UK Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 Germany Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 Spain Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Italy Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 France Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 Rest of Europe Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 China Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 Japan Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 India Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 Australia Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 South Korea Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 Rest of Asia Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Brazil Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 Mexico Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Rest of Latin America Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 GCC Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 29 Africa Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030
  • FIG. 30 Rest of Middle East and Africa Alpha Thalassemia Treatment Market (US$ Million), 2020 - 2030